Takeda Deepens Links As London Touts Life Science Credentials
This article was originally published in PharmAsia News
The UK, and London in particular, supported by its mayor, is making a major push in Japan for life sciences collaboration and investment, as part of which a new academic research collaboration involving Takeda has been unveiled that deepens the Japanese firm's UK links.
You may also be interested in...
As it reported solid underlying growth in the fiscal first quarter, Takeda has unveiled a detailed implementation program for its stated strategic intent to refocus global R&D effort on selected R&D areas, in a major overhaul that will make much wider use of external partners and affect "significant" numbers of people across the company.
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.